These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10352919)

  • 1. Ovarian and adrenal function in polycystic ovary syndrome.
    Rosenfield RL
    Endocrinol Metab Clin North Am; 1999 Jun; 28(2):265-93. PubMed ID: 10352919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal involvement in polycystic ovary syndrome.
    Gonzalez F
    Semin Reprod Endocrinol; 1997 May; 15(2):137-57. PubMed ID: 9165658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian and adrenal hyperandrogenism.
    Carmina E
    Ann N Y Acad Sci; 2006 Dec; 1092():130-7. PubMed ID: 17308139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome.
    Fruzzetti F; De Lorenzo D; Ricci C; Teti G
    Fertil Steril; 1995 Apr; 63(4):734-41. PubMed ID: 7890056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
    Rosenfield RL; Ehrmann DA; Barnes RB; Sheikh Z
    Ann N Y Acad Sci; 1993 May; 687():162-81. PubMed ID: 8323171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
    Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
    Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
    Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T; Honour JW; Conway GS
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytochrome P450c17 in polycystic ovary syndrome.
    Qin KN; Rosenfield RL
    Mol Cell Endocrinol; 1998 Oct; 145(1-2):111-21. PubMed ID: 9922107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome.
    Gonzalez F; Chang L; Horab T; Lobo RA
    Fertil Steril; 1996 Sep; 66(3):354-61. PubMed ID: 8751729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
    Rosenfield RL; Barnes RB; Ehrmann DA
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.
    Suikkari AM; MacLachlan V; Montalto J; Calderon I; Healy DL; McLachlan RI
    Hum Reprod; 1995 Mar; 10(3):513-9. PubMed ID: 7782424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ovary and adrenal glands in hyperandrogenemia in patients with polycystic ovary syndrome.
    Kamel N; Tonyukuk V; Emral R; Corapçioğlu D; Baştemir M; Güllü S
    Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):115-21. PubMed ID: 15772904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome.
    Barnes RB
    Semin Reprod Endocrinol; 1997 May; 15(2):159-68. PubMed ID: 9165659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome.
    Rosenfield RL; Barnes RB; Cara JF; Lucky AW
    Fertil Steril; 1990 May; 53(5):785-91. PubMed ID: 2185040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
    Zhou R; Bird IM; Dumesic DA; Abbott DH
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.